secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001628280-23-036697
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports updated Phase 1/2 Alta data for hemophilia A gene therapy; FVIII maintained through ~4 years
--------------------------------------------------------------------------------

- Single infusion of giroctocogene fitelparvovec (3e13 vg/kg) maintains FVIII activity in mild-to-normal range through up to 208 weeks.
- Mean annualized bleeding rate in high-dose cohort was 0 in year 1 and 1.2 overall; no participants resumed prophylaxis.
- No confirmed FVIII inhibitor development, no thrombotic events, and liver safety resolved without sequelae.
- Pfizer expects pivotal Phase 3 AFFINE trial readout in mid-2024.
- Updated data to be presented at ASH Annual Meeting on December 11, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023036697/0001628280-23-036697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023036697/sgmo-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-036697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer